Health Effects of Increasing Muscle Activation While Sitting in Office Workers
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 11/14/2018 |
| Start Date: | August 2016 |
| End Date: | June 2017 |
Previous research suggests that prolonged sitting increases risk for cardiometabolic diseases
and the risk factors associated with cardiometabolic diseases. However, no study to date has
examined if a chronic intervention that breaks up prolonged sitting in a real-world
environment results in a reduction in the metabolic risk factors associated with
cardiometabolic diseases. Thus, the objective of this study is to examine the potential
health benefits of breaking up sitting bouts throughout the workday using a small cycling
device (DeskCycle) in office workers involved with jobs that require prolonged bouts of
sitting. The investigators hypothesize that breaking up sitting will be associated with
improvements in cardiometabolic disease risk factors. More specifically, the investigators
hypothesize that breaking up sitting will decrease blood glucose during an oral glucose
tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure,
decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol,
and triglycerides.
and the risk factors associated with cardiometabolic diseases. However, no study to date has
examined if a chronic intervention that breaks up prolonged sitting in a real-world
environment results in a reduction in the metabolic risk factors associated with
cardiometabolic diseases. Thus, the objective of this study is to examine the potential
health benefits of breaking up sitting bouts throughout the workday using a small cycling
device (DeskCycle) in office workers involved with jobs that require prolonged bouts of
sitting. The investigators hypothesize that breaking up sitting will be associated with
improvements in cardiometabolic disease risk factors. More specifically, the investigators
hypothesize that breaking up sitting will decrease blood glucose during an oral glucose
tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure,
decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol,
and triglycerides.
Inclusion Criteria:
- Both males and females
- Subjects will need to be 18-55 years old
- Subjects will need to be sitting at least 6 hours/day on 5 days/week
- Subjects will need to be exercising less than 5 hour/week
Exclusion Criteria:
- Females that are pregnant or breast-feeding.
- Subjects must be free from any acute or chronic physical condition that would
influence the outcome measures of the protocol. Examples include, but are not limited
to advanced chronic disease states (chronic kidney, liver, heart, or lung disease),
morbid obesity, emphysema, and an inability to use the legs for normal locomotion.
Normality will be established on the basis of clinical history, physical exam, and
vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease
or symptoms of active illness will be excluded from study. Any subject with a history
of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or
symptoms of active illness will be excluded from study.
- Subjects will be excluded if they have a fasted blood glucose level >126 mg/dl or
a systolic blood pressure >140 mmHg.
- Medical/psychiatric/sleep disorders history: any clinically significant unstable
medical or psychological condition within the last year (treated or untreated).
- Drug use:
- Use of any medications, including over-the-counter and herbal products, that may
affect metabolic function within 1 month prior to the study or need to use any of
these medications at any time during the study (self-report by interview).
Examples of potential medications that will exclude a subject include:
beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones,
alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV
inhibitors. Note, subjects may be tested at a later date.
- Use of any investigational drug within 1 month before the study
We found this trial at
1
site
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
Click here to add this to my saved trials
